Sexual assaults facilitated by drugs or alcohol. by unknown
Differences in patterns 
of drug use between 
women and men
Key findings
Introduction
Cannabis
Ecstasy
Tranquillisers and sedatives
Alcohol and drug comparisons
Use of drug treatment services
Discussion
1
2
4
9
11
13
15
17
Differences in patterns 
of drug use between 
women and men
© European Monitoring Centre for Drugs and Drug Addiction, 2005. Reproduction is authorised provided the source is acknowledged.
Males outnumber females among drug users 
and clients attending drug treatment services.
Male to female ratios vary in magnitude 
across different countries in the European 
Union.
Among female school students, lifetime 
prevalence for cannabis and ecstasy are 
closer to those of their male counterparts than 
is the case for adults. 
Country variations in the gender ratio are 
more marked among adults than among 15-
to 16-year-olds and more marked for ecstasy 
than for cannabis.
The number of females in relation to males 
tends to increase as prevalence of drug use 
increases.
The number of females in relation to males 
is generally lower for the more illegal drugs 
and recent or frequent patterns of drug use. 
Increases in drug use among 15- to 16-year-
old males are usually accompanied by 
increases among females but tend to occur 
earlier or more rapidly among males.
Most of the care provided by drug treatment 
services is for opiate, cocaine and cannabis 
problems, for which male clients far outnumber 
females.
The proportions of females among clients 
receiving drug treatment are highest among 
young (under 20 years old) clients with 
problems relating to amphetamine-type 
stimulant (ATS) drugs and among older (over 
39 years old) clients with problems resulting 
from the use of sedative (pharmaceutical)
drugs.
Technical note  
Differences between males and females are presented here as ratios of prevalence among males 
over females.  Ratios higher than 1 indicate more males than females, for example a ratio of 2 
indicates twice as many males than females.  Ratios less than 1 indicate more females than males 
so that a ratio of 0.5 will indicate twice as many females as males. (Diagrams are drawn with 
logarithmic scaling.)
Typically three observational time windows are used by studies of illicit drug consumption. These 
are ever use or lifetime prevalence (LTP), recent use defined as use in the last year (LYP) and 
current use defined as use in the last month or 30 days (LMP) before interview. Lifetime prevalence 
indicates, at least, experimental use.
Key findings
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In this technical data sheet gender differences are explored in European data from three sources: 
school surveys (1), general population surveys (2) and drug treatment services (3) in the European 
Union. These data suggest that gender differences among people using drugs and attending 
drug treatment services, and the magnitude of these differences, are linked to a number of 
different factors. Here the impact of national situation, age of drug user and types of drug 
used on observed differences in patterns of drug consumption is explored in detail. Clearly, 
other factors are also likely to be important in influencing these male to female ratios. The 
EMCDDA will be preparing a more extensive special issue on gender in 2006 as part of its 
annual reporting exercise.
Gender differences in both prevalence of drug use and prevalence of treatment attendance 
vary considerably by country. For example, in Cyprus, men attending drug treatment services 
outnumber women by 9:1, compared with Hungary, where the ratio is much lower (1.6:1).
Age also influences the size of the gender 
difference: in many countries, the difference 
in lifetime experience of cannabis use is lower 
between male and female school students 
than between males and females in the general 
adult population (aged 15–64). In general, 
males outnumber females in estimates of 
cannabis use but females outnumber males 
in estimates for the use of pharmaceutical 
tranquillisers and sedatives. Male–female 
differences also vary with different patterns 
of drug use (Figure 1). For example, male 
predominance is greater for recent or frequent 
drug use than for occasional or experimental 
drug use.
Among clients of drug treatment services, the 
proportion of males attending with cannabis, 
cocaine and opiate problems is higher than 
the proportion with ATS (4) problems. And in 
some countries female clients being treated 
for problems with hypnotic and sedative drugs 
outnumber males.
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In the European Union men are more likely than women to use illicit drugs. 
Gender differences in patterns of drug use are often considerable and are 
reflected in the fact that among the clients of drug treatment services the 
proportion of women is only around 20%.
Introduction
(1) ESPAD (the European School Survey 
Project on Alcohol and Other Drugs) 1995, 
1999 and 2005 (See 
http://www.espad.org/method.html       
for details).
(2) There are harmonised instruments to 
collect data on drug use in the general 
population in European Union Member 
States (See 
http://www.emcdda.eu.int/?nnodeid=1380 
for details).
(3) There are harmonised instruments to 
collect data on drug treatment clients in 
European Union Member States (See 
http://www.emcdda.eu.int/?nnodeid=1420 
for details).
(4) The term ATS is used to refer to 
amphetamine-type stimulants – this group 
includes the ecstasy group of drugs, 
amphetamine and methamphetamine.
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Figure 1 
Comparison of male to female ratios for 15- to 16-year-old students and all 
adults, LTP cannabis
Male to female ratios (log scale) LTP % all adults
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This figure shows that the male predominance seen in adults at low prevalence levels is less 
evident among students.
Notes
Countries are ordered by increasing levels of prevalence (LTP, all adults) according to the 2004 
Statistical bulletin (right-hand axis). Their male to female ratios are plotted on a logarithmic scale 
(left-hand axis), and most are greater than 1.0 (equality).
Sources
15- to 16-year-old students, ESPAD 2003; all adults (15–64 years old), 2004 EMCDDA Statistical 
bulletin.
ESPAD 2003 figures for Germany are based on six regions only (Bavaria, Brandenburg, Berlin, 
Hesse, Mecklenburg-Western Pomerania and Thuringia).
In Europe, the vast majority of those young people that have tried an illicit 
drug have used cannabis, and males are generally more likely to have done 
so than females. Depending on the specific age group and gender, lifetime 
prevalence for having used cannabis at least once ranges from 2% of 15- 
to 16-year-old-female students in Cyprus to 50–52% of young adult males 
in the United Kingdom and Denmark.
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Cannabis
Males outnumber females for lifetime 
experience of cannabis in most of the 
countries surveyed. Among school students 
aged 15–16 years, more males have lifetime 
experience of cannabis than females in all 
but three countries (Ireland, Finland and 
Norway). School student male to female ratios 
are fairly consistent across most countries in 
the European Union, ranging from 1.0 in 
Ireland, Finland and Norway to 1.8 in 
Portugal. However, gender differences for 
lifetime experience (LTP) of cannabis use 
among all adults (aged 15–64) reveal 
considerably greater variations across 
countries, in that male to female ratios range 
from 1.25 in Finland to 4.0 in Estonia. In 
European Union countries with relatively high 
prevalence rates, the difference between male 
and female adults tends to be less marked 
than in countries with low prevalence rates. 
Conversely, larger gender differences among 
adults tend to be reported in countries with 
relatively low lifetime prevalence for cannabis. 
These are largely the new European Union 
Member States (with the exception of the 
Czech Republic and Slovenia), together with 
Greece and Portugal. Sweden, Norway and 
Finland are exceptions as prevalence is 
relatively low and male–female differences 
minimal (Figure 1). 
Data also show an increase in male–female 
differences from young to older age groups. 
Ratios for lifetime experience of cannabis 
increase from a range of 1.0–1.8 among 15-
to 16-year-old school students to 1.25–4.0 
among all adults.
The predominance of males over females 
increases as the observation time frame is 
shortened from lifetime use through recent 
(LYP) to current use (during the last 30 days). 
Male–female differences for lifetime 
experience (LTP) range from 1.2 to 4.0, 
whereas recent use (LYP) ranges from 1.5 in 
Finland to 4.3 in Hungary. In the case of 
current use, the male–female ratios are even 
higher, ranging from 1.8 in Norway to 5.9 
in Portugal. However, caution is required in 
interpreting these figures as random variations 
may be high as a result of the low numbers 
reported for recent and current use (Figure 2). 
Among 15- to 16-year-old school students, 
sex ratio differences are considerably greater 
for the ‘frequent use’ of cannabis (40+ times 
during a lifetime) as compared with those 
found for lifetime prevalence or last year 
prevalence. In some countries, male students 
are twice, three times and, in one country, 
even four times as prevalent as females in 
the frequent use group. Again some caution 
is needed in interpreting these results because 
of the relatively small numbers of students 
reporting frequent use involved (Figure 3).
Since 1995 the most marked, continuous 
increases in lifetime experience of cannabis 
among both male and female school students 
have taken place in the Czech Republic, 
Estonia, France, Slovenia and the Slovak
Republic. Although increases generally occurred in parallel among both male and female 
students, Figure 4 illustrates that in 2003 lifetime prevalence for cannabis loses the strong male 
predominance in high-prevalence countries and where there are substantial changes from 1995 
it is generally towards more equality between males and females. 
The ratio of males to females among clients attending drug treatment services for cannabis 
problems is higher than that for drug treatment in general and is particularly high among 
younger people. Variations between countries are evident, with the highest male to female 
ratios reported in Spain and the lowest in Slovenia (Figure 5).
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Countries are ordered by increasing 
levels of prevalence (LTP, all adults) 
according to the 2004 Statistical 
bulletin (right-hand axis). Their male 
to female ratios are plotted on a 
logarithmic scale (left-hand axis), and 
all are greater than 1.0 (equality).
Figure 2 
Male to female ratios for all adults, LTP, LYP and LMP cannabis
LTP %Male to female ratios (log scale)
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This figure shows that, among adults, the male–female ratio is lower for experimental (LTP) 
use than for last year use and is generally greatest for use during the past month. The correlation 
with lifetime prevalence is 0.82 (log-odds transforms).
Notes
Countries are ordered by increasing levels of prevalence (LTP, all adults) according to the 2004 
Statistical bulletin (right-hand axis). Their male to female ratios are plotted on a logarithmic scale 
(left-hand axis), and all are greater than 1.0 (equality).
Sources
2004 EMCDDA Statistical bulletin. 
In Belgium no dat  are available for last year's prevalence.
In the Czech Republic no data are available for last month's prevalence.
Figure 3 
Male to female ratios for 15- to 16-year-old students for experimental (LTP) 
and repeated (40+ in lifetime) cannabis use, 2003
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This figure shows that male–female differences in experimental (LTP) use are lower in countries 
with high prevalence levels but that repeated (40+ in lifetime) use is higher among males in 
all countries from where date are available (except Ireland).
Notes
Countries are ordered by increasing levels of prevalence (LTP) of all students in 2003 (right-hand 
axis). Their male to female ratios are plotted on a logarithmic scale (left-hand axis), and most 
are greater than 1.0 (equality).
Sources
15- to 16-year-old students, ESPAD 2003.
Figures for Germany are based on six regions only (Bavaria, Brandenburg, Berlin, Hesse, 
Mecklenburg-Western Pomerania and Thuringia).
Data on 40+ times in lifetime use are not available from Spain.  
In Cyprus, Sweden, Finland, Lithuania, Latvia and Estonia repeated use ratios could not be 
computed because of a zero prevalence.
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Figure 4 
Comparison of male to female ratios for 1995 and 2003 among 15- to 16-
year-old students, LTP cannabis (ESPAD surveys)
This figure shows that, in 2003, the strong male predominance of LTP found in high-prevalence 
countries was eliminated and that the substantial changes occurring after 1995 tended to 
increase the equality of use among males and females.
Notes
Countries are ordered by increasing levels of prevalence (LTP) in 2003 (right-hand axis). Their 
male to female ratios are plotted on a logarithmic scale (left-hand axis) and are almost always 
greater than 1.0 (equality).
Sources
ESPAD 1995 and 2003.
Male to female ratios (log scale) LTP % all students
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Figure 5 
Male to female ratios among new clients demanding treatment for cannabis 
in outpatient treatment centres by country (no. clients where primary drug 
was known), 2002
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This figure shows that the male predominance of cannabis use is higher than the male 
predominance of general drug use in all countries except Slovenia. It should be noted that male 
to female ratios are based largely on data from the Czech Republic, Germany and the 
Netherlands.
Notes
Countries are ordered by increasing levels of prevalence (LTP, all adults) according to the 2004 
Statistical bulletin (right-hand axis). Their male to female ratios are plotted on a logarithmic scale 
(left-hand axis), and all are greater than 1.0 (equality).
Sources
2002 TDI outpatient centres, REITOX national reports, 2003, n = 20 279.
Male to female ratios (log scale) LTP % cannabis all adults
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Variations in male to female ratios across 
countries are more marked for ecstasy use 
than for cannabis use, and this applies to 
both school students and adults. In over half 
of the European Union countries reported 
here, lifetime experience of ecstasy use is 
the same in 15- to 16-year-old female and 
male students, and in Finland the figure for 
females is twice that of males, albeit the 
prevalence rates are very low and therefore 
caution should be use in interpreting this 
data. In the remaining countries, where male 
student ecstasy users outnumber females, 
ratios range from 1.3 in France to 2.0 in 
Denmark, Greece, Italy, the Netherlands and 
Sweden. Among all adults (15–64 years) in 
most of the European Union countries 
surveyed, lifetime experience of ecstasy is 
generally lower among females than males. 
However, gender differences for lifetime 
experience (LTP) of ecstasy use reveal even 
greater variations across countries than for 
cannabis. Male to female ratios range from 
1.6 in Italy to 6 in Poland (Figure 6).
As with cannabis, there is a progressive 
increase in male to female ratios for lifetime 
experience of ecstasy with increasing age. 
Ratios increase from a range of 0.5–2.0 
among 15- to 16-year-old school students to 
a range of 1.0–6.0 among all adults (see 
Figure 6).
Figures for recent ecstasy use are low. In 
contrast to cannabis, gender differences are 
generally lower (range 1.0–4.30) for recent 
use (LYP) than for lifetime experience (LTP) 
(range 1.0–6.0). Among all adults the 
predominance of males is higher for recent 
use than for lifetime use in about half of the 
countries with information available.
Since 1995, small but continuous increases 
in the lifetime use of ecstasy among school 
students have taken place in the Czech 
Republic, Estonia and Portugal. These have 
occurred largely in parallel among both male 
and female school students.
Ecstasy is not a commonly reported drug for 
which individuals seek help at specialised 
drug treatment services in Europe. Of those 
who do, the proportion of females is generally 
higher than for those seeking help with 
problems with other drugs, but there are 
considerable variations between countries 
and no simple pattern is observable.
Overall prevalence rates for ecstasy are much lower than for cannabis 
although considerable inter-country variation exists. Reported rates for those 
who have ever used ecstasy (LTP) range from 0.1% among adult females 
(15–64 years old) in Sweden to 17.3% of young adult males (16–34 years 
old) in the United Kingdom.
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Ecstasy
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Figure 6 
Male to female ratios for 15- to 16-year-old students and all adults, LTP 
ecstasy
This figure shows that there is a tendency towards male predominance of ecstasy use among 
adults, although prevalence is low, and probably no gender difference at all among students.
Notes
Countries are ordered by increasing levels of prevalence (LTP) of all students in 2003 (right-hand 
axis). Their male to female ratios are plotted on a logarithmic scale (left-hand axis), and adult 
ratios in no country are less than 1.0 (equality), in contrast to student ratios.
Sources
15- to16-year-old students, ESPAD 2003; all adults (15–64 years old), 2004 EMCDDA Statistical 
bulletin.
ESPAD 2003 figures for Germany are based on six regions only (Bavaria, Brandenburg, Berlin, 
Hesse, Mecklenburg-Western Pomerania and Thuringia).
Male to female ratios (log scale) LTP % all adults
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Among school students (aged 15–16 years) 
in the European Union, surveyed by ESPAD, 
the prevalence of lifetime experience of 
tranquillisers or sedatives without a doctor’s 
prescription ranges from 1–2% of females in 
Cyprus, Ireland, Germany, Austria and the 
United Kingdom to 18% and 22% of females 
in Lithuania and Poland respectively. In 
contrast to other forms of drug use, use of 
tranquillisers and sedatives is higher among 
female school students than among male 
students in all the European Union countries 
surveyed with the exception of four Member 
States (Cyprus, Ireland, Norway and the 
United Kingdom). In the United Kingdom 
tranquilliser and sedative use is twice as high 
among males as among females, but 
prevalence estimates for the use of this type 
of illicit substance are very low, and the 
difference has to be interpreted in this context 
(see Figure 7).
Between 1995, 1999 and 2003, falls in 
prevalence generally outnumber increases 
but few consistent changes are observable 
in school students’ use of tranquillisers or 
sedatives without a doctor’s prescription. 
Only Estonia experienced a substantial 
increase, which was mainly among female 
students. 
Relatively low numbers of people in the 
European Union are reported to be receiving 
treatment for problems related to the illicit 
use of sedative drugs. In general, among 
those countries reporting, no clear differences 
stand out with the exception of treatment for 
barbiturate problems, which is concentrated 
to a large extent in the Czech Republic and 
Hungary. Male to female ratios are relatively 
low compared with clients seeking treatment 
for other types of drug use, ranging from 0.2 
in Latvia to 1.9 in Ireland. Nearly 50% of all 
females receiving treatment for this type of 
drug problem are over 39 years old but, 
again, the overall number reporting is low.
Tranquillisers and sedatives can be used both legally as prescribed medicine 
and illicitly without a doctor’s prescription. Comparable data on gender 
differences for this type of behaviour are not available from adult population 
surveys.
Tranquillisers and sedatives
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Figure 7 
Male to female ratios for 15- to 16-year-old students, LTP tranquillisers or 
sedatives without a doctor's prescription, 2003
This figure shows that, unlike the situation for illegal drugs, the proportion of female students 
who have ever used tranquillisers or sedatives without a doctor's prescription is greater than 
that for males
Male to female ratios (log scale) LTP %
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Notes
Countries are ordered by increasing levels of prevalence (LTP) of all students in 2003 (right-hand 
axis). Their male to female ratios are plotted on a logarithmic scale (left-hand axis), and most 
are less than 1.0 (equality).
Sources
ESPAD 2003.
Figures for Germany are based on six regions only (Bavaria, Brandenburg, Berlin, Hesse, 
Mecklenburg-Western Pomerania and Thuringia).
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Figure 8 
Male to female ratios for 15- to 16-year-old students, LTP and ‘repeated’ 
use of cannabis, and drinking 5 or more drinks in one session, 2003
This figure shows that current experience (last 30 days) among 15- to 16-year-olds of drinking 
five or more drinks in one session is higher in males than in females except in three countries 
(Ireland, United Kingdom and Norway). In general, male predominance is lower in those
Alcohol and drug comparisons
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In most countries the vast majority 
(90% or more) of 15- to 16-year-
old students have drunk alcohol at 
least once in their lifetime. 
The frequency of consuming five or more 
drinks in a row during the past 30 days 
provides one measure of potentially more 
problematic alcohol use. Among 15- to 16-
year-old students the current prevalence (at 
least once during the previous 30 days) of 
consumption of five or more drinks in a row 
ranges from 15% among females in Poland 
to 67% among males in Denmark.
Among school students aged 15–16 years, 
more males than females have current 
experience of drinking five or more drinks in 
one session, except in three countries (Ireland, 
the United Kingdom and Norway). In general, 
male predominance is lower in those countries 
where the prevalence rates on this measure 
are highest. The range of the gender 
difference is similar to that for cannabis (LTP), 
varying from 1.0 or under in Ireland, the 
United Kingdom and Norway to 2.3 in 
Poland. The gender ratios for this measure 
and for lifetime prevalence of cannabis use 
are broadly similar among different countries 
(a log scale correlation of 0.46). In contrast, 
the gender ratio for frequent cannabis use is 
higher and shows no clear correlation across 
countries with this measure of experience of 
repeat drinking (Figure 8).
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countries where the prevalence of drinking five or more alcoholic drinks in one session is 
highest. The gender ratios for this measure and for cannabis lifetime prevalence across countries 
are broadly similar (a log scale correlation of 0.46). In contrast, the ratio for ‘repeated’ cannabis 
use is higher and shows no clear correlation across countries.
Sources
ESPAD 2003.
In Cyprus, Sweden, Finland, Lithuania, Latvia and Estonia ratios could not be computed because 
of a zero prevalence.
Use of drug treatment services
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Data provided by treatment services in the European Union, as in most other 
parts of the world, demonstrate that male clients far outnumber female clients 
(Figure 9).
Self-referral and referral from family and friends are the most common routes for clients to 
access drug treatment services regardless of sex. However, males account for more than 90% 
of referrals originating from the criminal justice system, which is overall the third most common 
route of referral to specialist drug services.
Figure 9 
Male to female ratios among new clients demanding treatment in outpatient 
centres in some European countries by age group for all drugs for which 
they sought treatment (no. of clients where age was known), 2002
This figure shows the overall age 
distribution of clients in treatment 
and demonstrates a male 
predominance at all ages     
(M:F 2:6).
Notes
Overall distribution shown (right-hand axis); male to female ratios are plotted on a logarithmic 
scale (left-hand axis) and are all greater than 1.0 (equality).
Sources
2002 TDI outpatient centres,  REITOX national reports, 2003.
Countries included: Cz, Dk, Fin, Ge, Gr, Hu, Ir, Lv, Nl, Sl, Sp, Sw. No. clients: 43 605
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Male to female ratios among clients attending 
drug treatment services in the European Union 
differ significantly between countries: from 
9.0 in Cyprus to 1.6 in Hungary. High male 
to female ratios are reported in Italy (6.5) 
and Spain (5.3) and relatively low ratios in 
the Czech Republic (2), Sweden (2.1) and 
Finland (2.6) (Figure 10).
The male–female ratio is higher among those 
seeking treatment primarily for problems with 
cocaine (5.8) and cannabis use (5.2) than 
among those with problems with opiate (3.7) 
and stimulant use (2.1). Females are more 
common among drug treatment service clients 
who have problems relating to use of 
amphetamine-type stimulants and sedative 
drugs than among clients receiving treatment 
for other drugs. Among those seeking 
treatment for problems with sedative-type 
drugs, females marginally outnumber males 
(0.9). It should also be noted that the ratio 
of females to males is greater among current 
injectors than among non-injectors. Male to 
female ratios are lowest in the under-20 and 
over-45 age groups, although no gender 
differences are found in the mean age of 
new clients (26.7 for males and 26.6 for 
females).
Female drug treatment clients report relatively 
higher educational levels than males, and 
females generally are less ‘economically 
active’ and more likely to be living with 
children than their male counterparts. In 
recent years, the proportion of females 
attending drug treatment services has 
increased in most European Union countries. 
The highest increases were reported in 
Germany, Greece, and the Netherlands. 
Almost no changes in male to female ratios 
were reported in Italy, Austria, Spain and
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Figure 10 
Male to female ratios among new clients attending drug treatment for all 
drugs by country in all types of treatment centres, 2002
This figure shows almost all the ratios between 2:1 and 6:1.
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Sources
Standard Table 3, REITOX national reports, 2003, n = 91891, all types of treatment centres.
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Discussion
The differences in the ratio of men to women found in the data presented 
above on different samples of illicit drug users raise some important issues 
for understanding patterns of illicit drug use in Europe. The EMCDDA will 
be addressing the topic of gender and drug use in a special focus issue in 
2006. This publication forms part of the preparatory work for that special 
issue and is intended to stimulate debate on the influence of gender in 
determining differences found in patterns of drug use across Europe.
Among the more interesting observations 
made is the fact that, for those who have 
ever used cannabis or ecstasy, male to female 
ratios tend to be consistently higher among 
surveys of the adult population than among 
studies of school students. In addition, there 
is some evidence in school surveys conducted 
in 1995 and 2003 suggesting a narrowing 
of the gap between males and females. Some 
of the increase in prevalence rates found in 
the most recent school surveys reflects a 
greater increase in female drug use than in 
male. This lends support to existing evidence 
of a generation–cohort effect, with more 
equality of drug-taking experience observed 
in recent years, at least among school 
students. However, considerable variation 
remains between countries, and this 
generation effect seems to apply less to recent 
or regular use than to lifetime use.  In those 
few countries where the male to female ratio 
among school students is increasing, both 
sexes show increasing prevalence but this is 
elevated among the male students. If young 
females are increasingly likely to experiment 
with drugs in the same manner as their male 
counterparts, this is indicative of a move 
towards more similar drug-taking patterns 
between the sexes in the future and could 
therefore be associated with a considerable 
increase in overall prevalence levels. 
Surveys among the adult population across 
many countries show a fairly consistent 
correlation between higher male to female 
ratios and lower overall prevalence for lifetime 
cannabis use. In part this reflects differing 
levels in the new Member States, which joined 
the European Union in 2004 compared with 
higher-prevalence Member States. However, 
the relationship of low prevalence of lifetime 
cannabis use with a higher male to female 
ratio does not generally hold among a number 
of mainly Northern European countries. There 
are exceptions in Sweden, Finland and 
Norway, where relatively low overall 
prevalence is accompanied by a more 
balanced ratio of males to females. This male 
predominance at low prevalence levels is not 
seen in other data, such as data from schools 
surveys and on other drugs and patterns of 
more recent drug use. It is not clear to what 
extent this pattern is determined by persistent 
cultural factors that make males 
disproportionately prone to illicit drug 
experimentation and to what extent it arises 
from the fact that in many of these countries 
drug use is a relatively recent historical 
phenomenon, developing first within the male 
populations.
With regard to more widely used drugs, there 
is some similarity between male to female 
ratios for school students who have ever used
cannabis and the ratios for those who drank five or more alcoholic drinks in a row during the 
past 30 days but this is not observable for recent or frequent cannabis use. This may suggest 
a common association of drug use with an outgoing lifestyle. Illicit use of legal drugs – 
tranquillisers and sedatives – shows a markedly higher proportion of female than male students 
using them without a doctor’s prescription. The exception is the United Kingdom, although this 
can probably be explained by the very low prevalence of tranquilliser and sedative use reported 
by United Kingdom students. Data from the different rounds of the ESPAD school survey suggest 
few consistent trends in the prevalence of tranquilliser or sedative use, although overall there 
is a downwards drift. It remains, however, a pattern of drug use that is poorly understood and 
in which females predominate; as such it merits future research attention. 
Data from outpatient drug treatment services show that the highest proportions of females 
receiving drug treatment are among young (under 20 years old) clients with problems relating 
to amphetamine-type stimulant (ATS) drugs and among older (over 39 years old) clients with 
problems resulting from the use of sedative (pharmaceutical) drugs. This suggests the importance 
of the following questions:
·Are drug treatment services less accessible to or efficacious for female clients over 
20 and under 40 years of age, a range particularly covering the child-rearing years? 
·Do females develop patterns of problem drug use that are markedly different from 
their male counterparts?
·To what extent are these figures artefacts of the collection methods in some of the 
contributing Member States?
Underlying trends in the data presented can be discerned only by taking a broad overview 
to take account of the considerable amount of between-country variation. But patterns are 
detectable, for example the ratio of females in relation to males tends to increase as prevalence 
of drug use increases and is generally lower for the more illegal drugs and for recent or frequent 
patterns of drug use. The trends suggest explanations linked to lifestyle influences intrinsically 
related to gender or age or to the dynamic factors that determine the development of drug 
fashions across Europe. Detailed analysis of male to female ratios can yield important information 
about changing lifestyles in relation to patterns of drug use and about the potential efficacy 
of drug prevention and treatment services for different client groups. It is essential to identify 
the influences of gender on the trends in order to understand their direction and develop 
appropriate responses.
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Sources
EMCDDA Annual report 2004 (http://annualreport.emcdda.eu.int).
EMCDDA Statistical bulletin 2004 (http://stats04.emcdda.eu.int).
ESPAD (The European School Survey Project on Alcohol and Other Drugs,1995,1999 and 2003) 
is co-ordinated by The Swedish Council for Information on Alcohol and Other Drugs. (CAN) and 
Council of Europe (Pompidou Group). For further details see http://www.espad.org/method.html
